Carboxy-Terminal Propeptide of Type 1 Procollagen (P1CP) and Carboxy-Terminal Telopeptide of Type 1 Collagen (1CTP) as Sensitive Markers of Bone Metabolism in Thyroid Disease

Endocrine Journal

Volumn 43, Issue 6, 1996, Pages 701-708

  Miyakawa, Megumi ^a   Tsushima, Toshio ^a   Demura, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Carboxy terminal propeptide of type 1 procollagen (P1CP); Carboxy terminal telopeptide of type 1 collagen (1CTP); Graves' disease; Hashimoto's disease

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; LIOTHYRONINE; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; THYROXINE;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; BLOOD; BONE; FEMALE; GRAVES DISEASE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OSTEOLYSIS; THYROID DISEASE;

ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; THYROID DISEASES; THYROIDITIS, AUTOIMMUNE; THYROXINE; TRIIODOTHYRONINE;

EID: 0030347744     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.43.701     Document Type: Article

References (31)

1. Triffitt JT (1987) The special proteins of the bone tissue. Clin Sci 72: 399-408.
2. Burgeson RE (1988) New collagens, new concepts (Review). Annu Rev Cell Biol 4: 551-577.
3. Prockop DJ, Kivirikko KI, Tuderman L, Guzman NA (1979) The bio-synthesis of collagen and its disorders (Review). N Engl J Med 301: 13-23.
4. Miyahara M, Njieha FK, Prockop DJ (1982) Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J Biol Chem 257: 8442-8448.
5. Melkko J, Niemi S, Risteli L, Risteli J (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328-1332.
6. Risteli J, Elomma I, Niemi S, Novamo A, Risteli L (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 39: 635-640.
7. Trivedi P, Risteli J, Risteli L, Hindmarsh PC, Brook CG, Mowat AP (1991) Serum concentration of the type I and III procollagen propeptide as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 30: 276-280.
8. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G (1992) Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 151: 764-768.
9. Taubman MB, Kammerman S, Goldberg B (1976) Radioimmunoassay of procollagen in serum of patients with Paget's disease of bone. Proc Soc Exp Biol Med 152: 284-287.
10. Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL (1984) Serum levels of Type I and II procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 58: 110-120.
11. Carey DE, Goldberg B, Ratzan SK, Rubin KR, Rowe DW (1985) Radioimmunoassay for Type I procollagen in growth hormone-deficient children before and during treatment with growth hormone. Pediatr Res 19: 8-11.
12. Legovini P, De Menis E, Da Rin G, Roiter I, Breda F, Artuso V, Di Virgilio R, Conte N (1994) Increased serum levels of carboxyterminal propeptide of type I collagen (P1CP) in hyperthyroidism. Horm Metab Res 26: 334-337.
13. Ebeling PR, Peterson JM, Riggs BL (1992) Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 7: 1243-1250.
14. Wenisch C, Bankl HC, Schonthal E, Myskiw D, Presterl E, Rumpold H, Graninger W (1995) Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. Clin Immunol Immunopatho 75: 225-230.
15. Parfitt AM, Simon LS, Villanueva AR, Krane SM (1987) Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 2: 427-436.
16. Eliksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J (1993) Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Miner Res 8: 127-132.
17. Charles P, Hasling C, Risteli J, Mosekilde L, Eriksen EF (1992) Assessment of bone formation by biocheminal markers in metabolic bone disease: Separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int. 51: 406-411.
18. Franklyn J, Betteridge J, Holder R, Daykin J, Paterson CR, Sheppard M (1994) Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol 41: 425-432.
19. Delmas PD, Wilson DM, Mann KG, Riggs BL (1983) Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab 57: 1028-1030.
20. Smedsrod B, Melkko J, Resteli L, Resteli J (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271: 345-350.
21. Paterson CR, Robins SP, Horobin JM, Preece PE, Cuschieri A (1991) Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64: 884-886.
22. Body JJ, Delmas PD (1992) Urinary pyridium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74: 471-475.
23. Harvey RD, McHardy KC, Reid IW, Paterson F, Bewsher PD, Duncan A, Robins SP (1991) Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 72: 1189-1191.
24. Elomaa I, Virkkunen P, Risteli L, Risteli J (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (1CTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66: 337-341.
25. Conti A, Monzani M, Persani L, Sartorio A (1994) Serum carboxyterminal cross-linked telopeptide of type I collagen in patients with thyroid disorders. Minerva Endocrinol 19: 127-131.
26. Persani L, Giammona E, Cortelazzi D, Beck-Peccoz P (1995) Carboxyterminal cross-linked telopeptide of type I collagen (1CTP) as an index of thyroid hormone effects on the bone. The 77th American Endocrine Meeting, Washington, DC. abstract P1-402.
27. Martin TJ, Wah Ng K, Suda T (1989) Bone cell physiology. Endocrin Metab Clin N Am 18: 833-858.
28. Grant DJ, McMurdo MET, Mole PA, Paterson CR (1995) Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol 43: 339-345.
29. Allain TJ, McGregor AM (1993) Thyroid hormones and bone. J Endocrinol 139: 9-19.
30. Mosekilde L, Melsen F, Bagger JP, Myhere-H Jensen O, Sorensen NS (1977) Bone changes in hyperthyroidism. Interrelationship between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol 85: 515-525.
31. Rosen CJ, Adler RA (1992) Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 75: 1531-1534.